PROTACs
ITI BioChem is specialized in providing Proteolysis targeting chimeras (PROTACs).
PROTACs have opened a new chapter for the development of new drugs and novel chemical knockdown tools and brought unprecedented opportunities to the industry and academia, which are heterobifunctional small molecules consisting of a ligand that binds to an E3 ligase, connected by a linker to another ligand that binds to the protein of interest (POI).
Comparison of PROTAC and Other Therapeutics
Advantages
PROTACs have opened a new chapter for the development of new drugs and novel chemical knockdown tools and brought unprecedented opportunities to the industry and academia, which are heterobifunctional small molecules consisting of a ligand that binds to an E3 ligase, connected by a linker to another ligand that binds to the protein of interest (POI).
Comparison of PROTAC and Other Therapeutics
Advantages
Degrade the "undruggable" protein target；
Overcoming drug resistance of cancer；
Eliminating both the enzymatic and nonenzymatic functions of the kinase；